Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Breakfast consumption led to a reverse metabolic state in individuals with type 2 diabetes.
Read More »Fasting Until Noon Increases Postprandial Glucose Levels, Impaired Insulin Response After Lunch and Dinner
Can Smaller Forks Help Diabetes Patients?
Patient, female, 54 years of age, type 2 diabetes and obesity, told me she thought her weight and subsequent type 2 diabetes related to overeating, especially large portions. She is being seen by a behavior therapist for her eating disorder. I started her on a GLP-1. Even at starting dose, she reported feeling more satiated, but still overeating. The dose was increased...
Read More »Chronically Elevated TNFα Level in Obese Patients Impairs Secretion of GLP-1
Anti-TNFα biologics might help to enhance GLP-1 secretion.
Read More »Increase in Osteoporosis Thought Due to Increase in DPP-4
Postmenopausal women with normal glucose tolerance focus of study.
Read More »GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Data establishes effectiveness of semaglutide in treatment of type 2 diabetes…. Novo Nordisk is currently the manufacturer for Victoza (liraglutide), a GLP-1 agonist that needs to be injected once daily. However, semaglutide only needed to be taken once weekly, which is more preferred. The main objective of the SUSTAIN-3 trial …
Read More »GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
A new study shows liraglutide mitigates the bone loss common with low calorie diets… Weight loss is frequently tied to reduced bone mass in adults who embark on a low calorie diet, putting them at increased risk of fractures following significant weight reduction. Furthermore, the reduction in bone mass does …
Read More »Investigational Drug ITCA 650, a GLP-1 Receptor Agonist, on the Way
Drug shows a significant reduction in HbA1c in patients with type 2 diabetes… A new investigational drug is underway to help with reduction of HbA1c, weight, and improve glycemic control in type 2 diabetes patients. ITCA 650 is an injection-free GLP-1 receptor agonist that provides continuous subcutaneous exenatide for 12 …
Read More »New GLP-1 Medication: Starting Low and Going Slow
Nausea is a common side effect of GLP-1 therapy. Recently a few of my patients took the recommended low starting dose, but got so nauseated they refused treatment beyond that. From this, I’ve learned to start my patients on half the low dose of the daily or twice daily GLP-1’s …
Read More »Patient’s Plan to “Stop All of My Medicine” Not a Good Idea…
The patient, a woman, 52 years of age, has type 2 diabetes and is on metformin, a GLP-1 agonist, and a long-acting insulin. Over the past few months, I’ve received calls and emails from her every now and then to let me know her glucose levels were rising, but whenever …
Read More »GLP-1 Analog May Help with NAFLD and Nonalcoholic Steatohepatitis
GLP-1 drug shows potential to treat both diseases… Nonalcoholic fatty liver disease (NAFLD), the most common form of chronic liver disease in America which affects approximately 30% of the population, is known to contribute to prediabetes and diabetes due to the liver’s important role in the regulation of blood sugar …
Read More »